Who is eligible for clinical trial NCT05951959?

Participants must meet protocol criteria for Mantle Cell Lymphoma (MCL). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05951959 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-28

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (NCT05951959)

A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

TrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation. Participants who progress during observation may receive retreatment with acalabrutinib

Who can join: Review the eligibility criteria below.

Location: Research Site — Hackensack, New Jersey

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

Research Site — Hackensack, New Jersey
Research Site — Stony Brook, New York
Research Site — Cleveland, Ohio
Research Site — Philadelphia, Pennsylvania
Research Site — Houston, Texas
Research Site — Heidelberg,
Research Site — Kogarah,
Research Site — Nedlands,
Research Site — Sydney,
Research Site — Porto Alegre,
Research Site — Rio de Janeiro,
Research Site — São Paulo,
Research Site — São Paulo,
Research Site — Edmonton, Alberta
Research Site — Vancouver, British Columbia
Research Site — Halifax, Nova Scotia
Research Site — Barrie, Ontario
Research Site — Toronto, Ontario
Research Site — Montreal, Quebec
Research Site — Gdynia,
Research Site — Krakow,
Research Site — Warsaw,
Research Site — Madrid,
Research Site — Birmingham,
Research Site — Gloucester,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Mantle Cell Lymphoma (MCL)

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL — Louisville, Kentucky
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma — Tampa, Florida
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting — Milwaukee, Wisconsin

Explore by condition: All Mantle Cell Lymphoma (MCL) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗